Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Enrolling by invitation × tislelizumab × Clear all

Phase

Status

Unknown 12 Completed 10 Recruiting 9 Not yet recruiting 6 Terminated 5 Active not recruiting 5 Withdrawn 2 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Radiotherapy 2 Lenalidomide 2 Carboplatin 2 tislelizumab 1 irinotecan sucrosofate 1 enzalutamide 1 Ruthenium-106 1 Radiotherapy, Intensity-Modulated 1 Paclitaxel 1 Melphalan 1 Mannitol 1 Leukocyte Count 1 Irinotecan 1 Folfox protocol 1 Dexamethasone 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06303583 2024-03-12

CRIS

Zhejiang Cancer Hospital

Phase 1/2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡